---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-041497"
form_type: "8-K"
ticker: "OBIO"
cik: "0001814114"
company_name: "Orchestra BioMed Holdings, Inc."
filed_at: "2022-07-26T23:59:59+00:00"
generated_at: "2026-06-24T08:50:53.137531+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HSAC2 gets redemption requests for 9.2M shares; RTW Funds buys 1M shares at $10.01 to back Orchestra BioMed deal

## Summary
- As of July 22, 2022, shareholders requested redemption of 9,237,883 HSAC2 ordinary shares ahead of July 26 vote on extension to Nov 6, 2022.
- RTW Funds (manager affiliate) purchased 1,000,000 HSAC2 shares at $10.01/share from an accredited investor in a private transaction.
- Purchase fulfills RTW's obligations under Forward Purchase Agreement with HSAC2 and Orchestra BioMed, and prevents redemption of those shares to retain trust funds.
- The action increases likelihood that the proposed business combination with Orchestra BioMed ultimately closes.
- The extension proposal would allow additional monthly extensions up to February 6, 2023.

## SEC filing metadata
- accession: 0001213900-22-041497
- form_type: 8-K
- ticker: OBIO
- cik: 0001814114
- company_name: Orchestra BioMed Holdings, Inc.
- filed_at: 2022-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814114/000121390022041497/0001213900-22-041497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814114/000121390022041497/ea163262-8k_healthsci2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-041497
- JSON: https://secwatch.observer/filing/0001213900-22-041497.json
- Plain text: https://secwatch.observer/filing/0001213900-22-041497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.